Executive Vice President, Head of Research & Development
Bill Mezzanotte, MD was appointed Head of Research and Development in October 2018. Bill is responsible for developing and executing CSL’s Research & Development strategy and portfolio, including the identification and development of all R&D platforms, skills and expertise necessary for success.
In April 2017, Bill joined the company as Head of Clinical Development, responsible for clinical science, statistics and clinical operations across CSL Behring's portfolio and then expanded his responsibilities to Head of Development, where he oversaw regulatory, project management, clinical science & operations, plasma, recombinant protein and gene therapy pharmaceutical development activities worldwide.
Prior to CSL, he was Senior Vice President and Therapeutic Area Head, Respiratory for Boehringer Ingelheim and spent 16 years with AstraZeneca in research and development, assuming roles of increasing leadership and management responsibility across multiple therapeutic areas.
Bill obtained his M.D. at the University of Pennsylvania and a Master of Public Health degree from Johns Hopkins University. He is board certified in internal medicine, pulmonary medicine, critical care medicine and sleep medicine and currently serves as a member of the Board of Directors of the Philadelphia-based University City Science Center.